Find therapies in clinical trials near you – page 3

Tambiciclib Added to Venetoclax and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia in Patients Who Did Not Respond After Two Treatment Cycles

Tambiciclib Added to Venetoclax and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia in Patients Who Did Not Respond After Two Treatment Cycles

A Study of Ivosidenib and Azacitidine for Patients Over 55 with Acute Myeloid Leukemia and IDH1 Mutation in Complete Remission

A Study of Ivosidenib and Azacitidine for Patients Over 55 with Acute Myeloid Leukemia and IDH1 Mutation in Complete Remission

Study on the Safety and Effects of AB8939 and Azacitidine for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Study on the Safety and Effects of AB8939 and Azacitidine for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Study of EP0042 alone and in combination with venetoclax and azacitidine in patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML)

Study of EP0042 alone and in combination with venetoclax and azacitidine in patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML)

Study on the Safety of Ivosidenib and Azacitidine for Adults with Newly Diagnosed IDH1m Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

Study on the Safety of Ivosidenib and Azacitidine for Adults with Newly Diagnosed IDH1m Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

Study of Bleximenib with Drug Combination for Patients with Acute Myeloid Leukemia with KMT2A or NPM1 Alterations

Study of Bleximenib with Drug Combination for Patients with Acute Myeloid Leukemia with KMT2A or NPM1 Alterations

Study on the Effectiveness and Safety of Azacitidine, Gemcitabine, and Bendamustine Hydrochloride for Patients with Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma

Study on the Effectiveness and Safety of Azacitidine, Gemcitabine, and Bendamustine Hydrochloride for Patients with Relapsed or Refractory Angioimmunoblastic T-cell Lymphoma

Study on the Safety and Effectiveness of Fedratinib and Azacitidine for Patients with Accelerated Phase Myelofibrosis

Study on the Safety and Effectiveness of Fedratinib and Azacitidine for Patients with Accelerated Phase Myelofibrosis

Study on the Safety and Effectiveness of Ivosidenib or Enasidenib with Azacitidine for Patients with Newly Diagnosed Acute Myeloid Leukemia with IDH1 or IDH2 Mutations

Study on the Safety and Effectiveness of Ivosidenib or Enasidenib with Azacitidine for Patients with Newly Diagnosed Acute Myeloid Leukemia with IDH1 or IDH2 Mutations

Study on Venetoclax, Azacitidine, and Cusatuzumab for Newly Diagnosed Acute Myeloid Leukemia Patients Not Suitable for Intensive Therapy

Study on Venetoclax, Azacitidine, and Cusatuzumab for Newly Diagnosed Acute Myeloid Leukemia Patients Not Suitable for Intensive Therapy

Study of ponatinib and azacitidine combination treatment in patients with accelerated phase or blast crisis chronic myelogenous leukemia

Study of ponatinib and azacitidine combination treatment in patients with accelerated phase or blast crisis chronic myelogenous leukemia

Study on the Effectiveness of Ivosidenib in Patients with IDH1 Mutated Myelodysplastic Syndrome